Consideration of the Ethnic Prevalence of Genotypes in the Clinical Use of Tacrolimus

References

• De Jonge H , NaesensM , KuypersDR . New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation . Ther. Drug Monit.31 ( 4 ), 416 – 435 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Antignac M , BarrouB , FarinottiR , LechatP , UrienS . Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients . Brit. J. Clin. Pharmacol.64 ( 6 ), 750 – 757 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dai Y , HebertMF , IsoherranenNet al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro . Drug Metab. Dispos.34 ( 5 ), 836 – 847 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kuehl P , ZhangJ , LinYet al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression . Nat. Genet.27 ( 4 ), 383 – 391 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Picard N , BerganS , MarquetPet al. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs . Ther. Drug Monit.38 ( Suppl. 1 ), S57 – S69 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Macphee IA , FredericksS , TaiTet al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation . Amer. J. Transplant.4 ( 6 ), 914 – 919 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Thervet E , LoriotMA , BarbierSet al. Optimization of initial tacrolimus dose using pharmacogenetic testing . Clin. Pharmacol. Ther.87 ( 6 ), 721 – 726 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Shuker N , BouamarR , Van SchaikRHet al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation . Amer. J. Transplant.16 ( 7 ), 2085 – 2096 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Van Gelder T , HesselinkDA . Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Clin. Pharmacol. Ther.87 ( 6 ), 640 – 641 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• De Jonge H , De LoorH , VerbekeK , VanrenterghemY , KuypersDR . In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients . Clin. Pharmacol. Ther.92 ( 3 ), 366 – 375 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Elens L , Van SchaikRH , PaninNet al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients . Pharmacogenomics12 ( 10 ), 1383 – 1396 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Werk AN , LefeldtS , BruckmuellerHet al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance . Clin. Pharmacol. Ther.95 ( 4 ), 416 – 422 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Organ Procurement and Transplantation Network . https://optn.transplant.hrsa.gov/ .
   Google Scholar
• Narayanan M , PankewyczO , ShihabF , WilandA , MccagueK , ChanL . Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study . Clin. Transplant.28 ( 2 ), 184 – 191 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Oetting WS , SchladtDP , GuanWet al. Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles . Amer. J. Transplant.16 ( 2 ), 574 – 582 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Tang JT , AndrewsLM , Van GelderTet al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations . Expert Opin. Drug Metab. Toxicol.12 ( 5 ), 555 – 565 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Vadivel N , GargA , HoltDW , ChangRW , MacpheeIA . Tacrolimus dose in black renal transplant recipients . Transplantation83 ( 7 ), 997 – 999 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Sanghavi K , BrundageRC , MillerMBet al. Genotype-guided tacrolimus dosing in African–American kidney transplant recipients . Pharmacogenomics J. doi:10.1038/tpj.2015.87 ( 2015 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Stein CM , SadequeAJ , MurrayJJ , WandelC , KimRB , WoodAJ . Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects . Clin. Pharmacol. Ther.69 ( 5 ), 317 – 323 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Andrews LM , RivaN , De WinterBCet al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients . Expert Opin. Drug Metab. Toxicol.11 ( 6 ), 921 – 936 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Passey C , BirnbaumAK , BrundageRC , OettingWS , IsraniAK , JacobsonPA . Dosing equation for tacrolimus using genetic variants and clinical factors . Brit. J. Clin. Pharmacol.72 ( 6 ), 948 – 957 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Boughton O , BorgulyaG , CecconiM , FredericksS , Moreton-ClackM , MacpheeIA . A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients . Brit. J. Clin. Pharmacol.76 ( 3 ), 425 – 431 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Nigro V , GlicklichA , WeinbergJ . Improved Bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation . Amer. J. Transplant.13 ( Suppl. 5 ), 339 ( 2013 ).
   Google Scholar
• Thörn M , FinnströmN , LundgrenS , RaneA , LööfL . Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract . Brit. J. Clin. Pharmacol.60 ( 1 ), 54 – 60 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Budde K , BunnapradistS , GrinyoJMet al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial . Amer. J. Transplant.14 ( 12 ), 2796 – 2806 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Langone A , SteinbergSM , GedalyRet al. Switching study of kidney transplant patients with tremor to LCP-Tacro (STRATO): an open-label, multicenter, prospective Phase 3b study . Clin. Transplant.29 ( 9 ), 796 – 805 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . www.ema.europa.eu/ .
   Google Scholar
• Trofe-Clark J , BrennanD , West-ThielkeP , MiloneM , LimM , BloomR . A randomized cross-over Phase 3b study of the pharmacokinetics of once-daily extended release MeltDose® tacrolimus (Envarsus® XR) versus twice-daily tacrolimus in African–Americans (ASERTAA) . Amer. J. Transplant.15 ( Suppl. 3 ), Abstract ( 2015 ). www.atcmeetingabstracts.com/ .
   PubMedGoogle Scholar